CME/CE Podcast: From Randomized Controlled Trials to Real-World: Biologics and Asthma

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:

https://www.mycme.com/courses/expert-interpretations-in-asthma-care-9014

Summary
Case discussions help translate clinical and research findings to the real world, and two pulmonologists’ perspectives on biologic selection and management in real world cases only furthers understand. Walk through two cases with Dr. Njira Lugogo and Dr. Diego Maselli moderated by NACE’s Dr Gregg Sherman. What would YOU do, when you hear the case presentations? Do the experts agree?

Learning Objectives 

• Review emerging data, including real-world and long-term extension studies, on biologic treatments for patients with severe asthma.
• Individualize biologic therapy selection for patients with severe asthma based on phenotype, comorbidities, and patient preferences.

This activity is accredited for CME/CE Credit.
Provided by the National Association for Continuing Education in partnership with the Association for Pulmonary Advanced Practice Providers.

The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.5 contact hour (which includes 0.5 hours of pharmacology).

For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.

Summary of Individual Disclosures
Dr. Lugogo has disclosed the following financial relationship:
Consultant: Amgen, AstraZeneca, Avillion, Genentech, GSK, Novartis, Regeneron, Sanofi, and Teva
Advisor: Amgen, AstraZeneca, Genentech, GSK, Regeneron, Sanofi, and Teva
Speaker: Honoraria for non-speaker’s bureau presentations from GSK and AstraZeneca
Contracted Research: Research support from Amgen, AstraZeneca, Avillion, Evidera, Gossamer Bio, Genentech, GSK, Janssen (COVID vaccine trials), Regeneron, Sanofi, Novartis and Teva was provided to my institution

All of her disclosures are related to asthma.

Dr. Maselli has disclosed the following financial relationships:
Consultant: Amgen (asthma), Regeneron/Sanofi (asthma), AstraZeneca (asthma, COPD), GSK (asthma, COPD)
Advisor: Amgen (asthma), Regeneron/Sanofi (asthma), AstraZeneca (asthma, COPD), GSK (asthma, COPD)
Speaker: Amgen (asthma), Regeneron/Sanofi (asthma), AstraZeneca (asthma, COPD), GSK (asthma, COPD)

Dr. Sherman has no relevant financial relationships to disclose.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.